Abstract | Opioids were one of the earliest classes of medications used for pain across a variety of conditions, but morbidity and mortality have been increasingly associated with their chronic use. Despite these negative consequences, chronic opioid use is increasing worldwide, with the USA and Canada having the highest rates. Chronic opioid use for noncancer pain can have particularly negative effects in the gastrointestinal and central nervous systems, including opioid-induced constipation, narcotic bowel syndrome, worsening psychopathology and addiction. This Review summarizes the evidence of opioid misuse in gastroenterology, including the lack of evidence of a benefit from these drugs, as well as the risk of harm and negative consequences of opioid use relative to the brain-gut axis. Guidelines for opioid management and alternative pharmacological and nonpharmacological strategies for pain management in patients with gastrointestinal disorders are also discussed. As chronic pain is complex and involves emotional and social factors, a multimodal approach targeting both pain intensity and quality of life is best.
Prescription opioid use has become a global epidemic. Between 2011 and 2013, opioid use more than doubled worldwide, with substantial increases occurring in North America, Europe and Oceania 1 . Despite the increasing trends worldwide, opioid consumption rates per capita in the USA and Canada far outpace those in other countries 2 (FIG. 1) . One reason cited for this difference is that, in the rest of the world, opioids are not as frequently prescribed for chronic pain syndromes as they are in North America 3 . Similar trends are occurring in the UK 4, 5 , and its rates of opioid consumption in 2010 are comparable to rates at the inception (1999) of the opioid crisis in the USA 6 . Postulated reasons for lower opioid consumption in countries with national health systems, which are publicly funded, are that doctors have less incentive to over-prescribe and that prescription records are stored centrally, enabling patient misuse to be detected more quickly 7 . The notable rise in opioid prescribing over the past 15 years in the USA relates in part to the report by The Joint Commission in 2000, which indicated that pain was inadequately treated and better pain manage ment was needed 8 . Notably, the commission provided little guidance on how best to achieve pain relief and did not recom mend that the approach should involve increased use of opioids. In addition, opioids are recommended treatments on the WHO's three step 'analgesic ladder' for cancer pain 9 ; however, this guideline has also been widely applied for managing chronic noncancer pain 10 . Although debate about the effectiveness of opioids in treating chronic noncancer pain exists, opioid misuse and overdose-related deaths continue to increase [11] [12] [13] . In 2014, >240 million opioid prescriptions were written 14 , and nearly 19,000 deaths related to opioid prescriptions were reported in the US -a 3.4-fold increase in deaths since 2001 (REF. 15 ). In addition to mortality, chronic use of opioids is associated with serious medical morbidities, including addiction, and increased related medical resource utilization [16] [17] [18] [19] . For example, in the USA, there was a nearly 300% increase in opioid-related emergency department visits between 2004 and 2011 (REF. 20) , and >520,000 hospitaliza tions related to opioid abuse and dependence were reported in 2012 17 . Australia also had a 2.4-fold increase in opioid-related hospitalizations between 1998 and 2009 (REF. 21 ).
In 2010, 15.5 million people had opioid dependence globally, with the highest rates in North America (292.1 per 100,000), Eastern Europe (288.4 per 100,000) and Australia (278.6 per 100,000) 22 . In China, although heroin addiction remains the largest opioid problem, polydrug use, including prescription opioids, is on the rise 23 . In the US, the prevalence of opioid dependence in patients receiving prescription opioids is as high as 26% in primary care 24, 25 , the estimated rate of opioid misuse is 21-29%, and the rate of addiction is 8-12% 18 . The estim ated rates of substance use disorder in patients with chronic pain seen in pain clinics are as high as 45% in the US 26, 27 . In addition, nearly 53% of patients receiving treatment for chronic pain in two pain centres in Israel were found to have problematic opioid use 28 . Chronic opioid use can be particularly detrimental to the gastrointestinal tract and central nervous system, particularly in patients with pre-existing gastro intestinal conditions 19, 29 . As opioids are prescribed predominantly in primary care and pain clinics 30, 31 , gastro enterologists often receive referral patients who are already on chronic opioid therapies. In fact, although gastroenterologists prescribe only 0.3% of opioids, the prevalence of pain is higher in individuals with gastro intestinal disorders than in the general public [32] [33] [34] . Estimates of chronic opioid use have ranged from 13% to nearly 50% in adults with IBD 33, 35, 36 and as high as 70% in hospital ized adult patients with IBD 37 . Rates of opioid use have been reported at >50% in patients with chronic pancreatitis 38 and at almost 20% in patients with IBS 39 . Among patients with chronic nonalcoholic pancreatitis, 39% had high scores on opioid misuse measures, with depressive symptoms, pain ratings, alcohol use and psychological quality of life being notable predictors 40 . Furthermore, prescription opioid use has been associated with increased hospitalization in patients with chronic pancreatitis 41 and with increased risk for infection in patients with Crohn's disease 36 .
As opioid use and misuse are continuing to gain recognition as a global problem, increased awareness of opioid-induced gastrointestinal problems is necessary 42, 43 . This Review summarizes the evidence of opioid misuse in gastroenterology, including the lack of evidence for a benefit from opioids and the risk of harm and negative consequences of opioid use relative to the brain-gut axis. Strategies to prevent opioid misuse, the treatment of pain for patients already on opioids and alternative intervention strategies for pain manage ment in patients with gastrointestinal disorders are also discussed.
Opioids for gastrointestinal disorders
The evidence supporting the effectiveness of opioids for short-term use (<3 months) for chronic non cancer pain is largely focused on musculoskeletal pain 44 . Evidence for the efficacy of opioids for gastrointestinal pain is lacking. In chronic pancreatitis, one small randomized study assessed short-term (5 days) use of tramadol versus morphine and found that 67% of the tramadol group, compared with 20% of the morphine group, reported analgesia as "excellent" (REF. 45 ). There is a lack of random ized controlled trials showing the efficacy of opioids for chronic abdominal pain; additionally, gastrointestinal disease has been identified as a major cause of oral opioid ineffectiveness due to malabsorption 46 . Furthermore, existing evidence underscores concerns related to problematic opioid use in individuals with gastrointestinal disorders. In a study of chronic opioid users with Crohn's disease, 37% of patients with a concurrent functional gastrointestinal disorder (FGID) diagnosis were identified to be misusing opioids, compared with 9.6% of those without an FGID diagnosis 47 . The increased rate of opioid misuse in these patients might be explained by the presence of prior psychiatric diagnoses 37 and/or as part of a dissociative coping style for those patients with prior trauma history -a factor that has been independently linked to increased rates of IBS 48 . Additionally, a large epidemiological study indicates that ~5% of patients with IBD will become heavy users of opioids within 10 years after diagnosis 49 . This finding is of particular concern as the risk for addiction in patients with noncancer pain increases with higher dosing (>120 mg morphine equivalent) and chronic opioid therapy 50 .
Opioid-induced gastrointestinal effects
Substantial evidence links opioid use to compounding and deleterious gastrointestinal-related adverse effects, collectively known as opioid-induced bowel dysfunction (OIBD). Among the most common opioid-induced gastro intestinal effects are constipation, nausea, abdominal pain or discomfort, gas, ileus, gall bladder contraction and gastro-oesophageal reflux 51, 52 . In addition, in a large observational study among 6,273 patients with Crohn's disease, opioid use was significantly (P < 0.001) associated with serious infections and was also a significant predictor of death 36 . In a study of 2,055 patients taking opioids for noncancer pain, 57% reported constipation, 13% reported nausea, 11% reported abdominal pain and 10% reported increased gas as the most bothersome opioid-associated symptoms 51 . Opioid-induced constipation (OIC) is the most frequently reported gastro intestinal adverse effect, with estimates ranging from 15-90% of individuals taking opioids 53, 54 . For instance, opioid users seeking care for abdominal pain in the emergency department were three times more likely than non-users to have constipation 55 . In addition, among 489 patients with chronic noncancer pain, OIC had a negative effect on quality of life, particularly on work performance and produc tivity (38%), performing activities of daily living (49%), social interactions (45%), sex lives (45%) and the ability to leave the house (43%) 56 .
Key points
• Prescription opioid use is a global epidemic, with substantial increases in opioid-related morbidity and mortality around the world • There is a lack of evidence supporting the use of opioids for the management of chronic abdominal pain • Opioid use can have deleterious consequences on the gastrointestinal tract, including opioid-induced constipation and narcotic bowel syndrome • Many promising non-opioid pharmacological and nonpharmacological alternatives for treating abdominal pain exist; however, additional research is needed to identify best practices for treating abdominal pain in individuals with gastrointestinal disorders • If opioids are prescribed, it is essential to have strategies to monitor and manage opioid misuse, continually monitor risk-benefit clinical profiles, and prevent and treat addiction
Other gastrointestinal symptoms reported with chronic opioid use are GERD (33%) 19 and opioid-induced oesophageal dysfunction 57 . In pooled data from two randomized controlled trials evaluating teduglutide (a glucagon-like peptide-2 analogue) in short-bowel syndrome (n = 136), patients taking opioids (n = 52) had significantly (P = 0.0009) greater adverse gastro intestinal effects than those who were not (51% versus 21% for abdominal pain, 42% versus 11% for nausea, 17% versus 8% for abdominal distension and 19% versus 6% for vomiting) 58 . The mechanisms underlying OIBD are complex but are primarily attributed to the high density of opioid receptors (μ-type, κ-type, δ-type) within the gastrointestinal tract, which, when activated, result in decreased motility and secretion 59, 60 (FIG. 2) . The effects of opioids on gastrointestinal motility (for example, delayed gastric emptying and slowing of intestinal transit) are associated predominantly with the activ ation of μ-opioid receptors in neurons of the enteric nervous system via cellular second-messenger systems such as cyclic AMP, chloride and potassium channels and protein kinases 29, 61 . Opioid receptor antagonists can modulate both excitatory and inhibitory neural inputs in the gastrointestinal tract 62 . This interaction involves neurotransmitters such as acetylcholine, vasoactive intestinal peptide (VIP), nitric oxide (NO) and 5-hydroxytryptamine (serotonin) 60 . Inhibition of excitatory pathways, such as those involving acetylcholine or substance P, leads to the blockade of distention-induced peristaltic contractions, whereas suppression of inhibitory pathways such as NO signalling results in disinhibition of smooth muscle activity, elevation of muscle tone and non propulsive motility (for example, spasms) 60, 63 . Activation of δ-opioid receptors might also be involved in decreased gastrointestinal motility by altering pyloric tone 29 
.
Gastrointestinal secretion is predominantly mediated by the three types of opioid receptors located in the gut wall 60 . Opioids activate the sympathetic nervous system and inhibit acetylcholine and VIP activity, resulting in reduced secretion 60 . Opioids also reduce epithelial secretion and promote the absorption of electrolytes and water, worsening constipation and abdominal distress or pain 64 . Morphine administration has been associated with increased sphincter contraction and reduction in the emptying of pancreatic juice and bile, causing delayed digestion 65, 66 . However, the effects of opioids on μ-opioid receptors in the lower oesophageal sphincter significantly (P < 0.05) decrease motility and pressure, resulting in oesophageal reflux 67, 68 . Collectively, these opioid-induced gastrointestinal effects lead to nausea, vomiting, delayed gastric emptying and constipation. In addition, sphincter of Oddi dysfunction via μ-opioid receptor stimulation might also result in pancreatitis, as reported in studies testing the mixed opioid drug eluxadoline in patients with IBS 69, 70 . Opioid use can also have deleterious effects for patients with liver diseases such as cirrhosis. Opioids are predominantly metabolized in the liver via oxidation, reduction or hydrolysis by the cytochrome P450 system (for example, CYP2D6, CYP2B6, CYP3A4); glucuronidation; or biliary excretion and elimination 71 . In a process known as the first-pass effect, orally ingested opioids, such as codeine, oxycodone and tramadol, are absorbed by the gastrointestinal tract and pass through the portal vein to undergo metabolism in the liver before the active metabolites of these medications reach the systemic circulation 72 . Hepatic dysfunction can result in reduced clearance of the drug from the blood or plasma and increased bioavailability and accumulation of the opioid 73 . A study in patients with cirrhosis who received an oral dose of morphine found that these patients had a mean elimination half-life of 5.5 h, compared with a mean of 3.3 h in a healthy control group (P < 0.05) 74 . The use of opioids in patients with liver disease can lead to, or aggrav ate, hepatic encephalopathy owing to the accumulation of opioid metabolites in the central nervous system 72, 75 . Opioid tolerance, defined as the state of adaptation in which exposure to a drug induces changes that result in diminution of one or more of the drug's effects over time 44 , can develop at different rates for different opioid-related effects. For instance, it develops quickly for effects such as nausea, sedation and cognitive impairment, whereas other effects such as constipation can occur much more slowly 76, 77 . There are also differences in tolerance between central and peripheral targets. For example, a lack of tolerance in the colon leads to opioid-induced chronic constipation, in contrast to more proximal regions of the gut and also the brain, in which adverse effects such as nausea, vomiting and sedation improve over time 60 . The rate of development of analgesic tolerance to opioids has not been as definitively determined, although some studies suggest that it might not be a pervasive problem in long-term opioid use for chronic pain 78 . Opioid-induced constipation. OIC is characterized as a change in baseline bowel habits, such as reduced bowel movement frequency, development or worsening of straining during bowel movements, a sense of incomplete rectal evacuation and/or a harder stool consistency 79 . Involvement of other areas of the gastrointestinal tract causing small bowel ileus or gastroparesis is part of the wider spectrum of OIBD, although the mechanism is the same as that of OIC 29 . The motility effects of opioids are mainly caused by μ-opioid receptors, which are found throughout the gastrointestinal tract, whereas μ-opioid receptors in the brain and spinal cord are involved in analgesia 29 . In OIC, the activation of μ-opioid receptors leads to reductions in gastric emptying, propulsive contractions of the intestines and secretions from the intestines, pancreas and gallbladder 79 . OIC is also partially mediated by changes in water absorption owing to the effects of opioids on chloride channels 80 . These processes, together with increased pyloric and anal sphincter tone, lead to the symptoms of constipation.
Narcotic bowel syndrome.
A growing number of studies report persistent abdominal pain in patients with chronic opioid use 19, 51 . A specific type of persistent, yet under-recognized, abdominal pain termed narcotic bowel syndrome (NBS) has been identified in 6.4% of patients in the US with chronic opioid use 19 . NBS is defined as chronic or frequently recurring abdominal pain treated with high-dose opioids 81 , and diagnostic criteria for clinical research are now available 82 . The nature or intensity of pain is not entirely due to diagnosis of a gastrointestinal disease, such as IBD or chronic pancreatitis, and even with pain resulting from another underlying diagnosis, there is an opioid-induced amplification of the pain 83 . To meet the diagnostic criteria for NBS, a patient must have had at least two of the following symptoms for the past 3 months with symptom onset at least 6 months before diagnosis: pain worsens or incompletely resolves with escalating doses of narcotics; there is a marked worsening of pain when the narcotic dose wanes and improvement when narcotics are re-initiated; and there is a progression of the frequency, duration and intensity of the pain episodes 84 . In addition to visceral pain that worsens with long-term or increasing doses of opioids, the hallmark symptom of NBS, other symptoms can include nausea, periodic vomiting, abdominal distension and constipation 83, 84 . The inclusion of NBS in the Rome IV diagnostic criteria of FGIDs as a centrally mediated abdominal pain disorder 85 will increase its visibility among clinicians who manage these conditions.
The diagnosis of NBS can also be complicated by other physiological processes. For example, NBS, as a painful disorder, needs to be differentiated from OIC, which is characterized by bowel dysfunction, although pain might also be present. NBS is mediated by effects of opioids on the central nervous system resulting in central hyperalgesia, whereas OIC is caused by the peripheral effects of opioids on μ-opioid receptors affecting motility of the gastrointestinal tract 83 . Abdominal pain can also worsen during physiological withdrawal from opioids, but in this case, the pain occurs together with other symptoms of withdrawal such as lacrimation, yawning, rhinorrhoea, sweating, restlessness and diarrhoea 86 . Tolerance to opioids leading to escalating dosing is a concern but is not itself linked to worsening pain 86 . The paradoxical increase in pain associated with opioid use that characterizes NBS has been explained through several putative mechanisms (FIG. 3) , including inflammatory glial cell activation in the dorsal horn 81, 87 , activation of excitatory pathways within a bimodal opioid regulation system 81, 88 and the descending facili tation of pain at the level of the rostral medulla along with pain facilitation via dynorphin or cholecystokinin activation 81, 89 . These mechanisms have been described in detail elsewhere [81] [82] [83] [84] 90 . Evidence suggests that chronic opioid use has compounding effects on glial cell activ ation and induction of visceral hyperalgesic effects 81 . Opioids bind directly to the μ-opioid receptors, which activate glia through the release of pro-inflammatory cytokines that bind to glial cell receptors, subsequently potentiating hyperalgesia 91 . In addition, opioids have been shown to have an indirect effect on glial cell activ ation in rats through the release of dynorphin within the spinal cord 92 . Furthermore, findings from a rat model of NBS supported morphineinduced spinal microglial activation caused by peripheral neuroimmune activation, and spinal dynorphin release mediated visceral hyperalgesia 93 . The activation of glial cells through Toll-like receptors (speci fically, TLR4) has also been shown to mediate neuropathic pain and other deleterious opioid effects such as hyperalgesia, tolerance and physical dependence [94] [95] [96] .
The bimodal opioid regulation system encompasses the excitatory and inhibitory effects on sensory neurons caused by opioids. This system is mediated by the stimulatory G protein-coupled receptors within the dorsal root ganglia 97 . Although opioids are generally considered to have inhibitory effects on afferent neurons and their signalling, evidence also suggests that chronic opioid use can induce excitatory effects (mediated by glutamate) on stimulatory G protein-coupled receptors, causing tolerance and hyperalgesia 81, 88, 97 .
Prevention and treatment considerations
Patients with chronic pain who request opioids pose an ethical dilemma to clinicians who strive to find a balance between adequate pain relief and the risks of misuse and abuse of opioids. The basic ethical obligation of providers is to acquire current knowledge, skills and tools to assist in making prescribing decisions and uphold the ethical principles of beneficence, nonmaleficence, autonomy and justice 98 . In the absence of strong research evidence supporting the chronic use of opioids for abdominal pain, it is critical that prescribers use objective factors to conduct risk-benefit analyses 99, 100 and not succumb to pressures to prescribe opioids only to increase patient satisfaction metrics 101, 102 . One study in 2016 revealed that emergency room physicians perceived pressure to prescribe opioids to avoid administrative criticism and poor patient satisfaction 103 . Primary prevention is the most effective way to control the opioid epidemic 104 . However, should opioid use be warranted, for example, in patients in which the therapeutic benefit outweighs the many risks, appropriate steps need to be taken to mitigate the risks associated with opioids and ensure that they are not used as a first-line approach for treatment of any chronic noncancer pain. An algorithm for cautious opioid prescribing has been previously published 100 , with key points highlighted in BOX 1. For patients who are already on opioids, recommended measures include repetitive monitoring of the risk-benefit ratio, optimizing non-opioid pain management strategies and tapering patients to the lowest possible opioid dose.
Opioid detoxification. As a first step in evaluating a pain treatment plan that includes opioids, an objective analysis of the risk-benefit ratio of chronic opioid prescription should be performed, and whenever possible, an opioid detoxification process to taper narcotic use should be considered. Published protocols outlining algorithms that use non-opioid strategies can help with chronic abdominal pain. Drossman et al. 105 demonstrated good short-term success with detoxification in patients with NBS, suggesting an opioid taper schedule of 10-33% reduction per day of morphine equivalent and attention to treating associated anxiety and withdrawal. During the opioid taper, short-term benzodiazepines for anxiety and agents such as clonidine for withdrawal symptoms were used 105 . This strategy should be used specifically for the purpose of detoxification, especially given an FDA warning in 2016 against prescribing opioids and benzodiazepines together on a chronic basis owing to synergistic brain-related adverse effects and an increased risk On the presynaptic side, opioids paradoxically activate 'on cells' projecting from the rostral ventromedial medulla leading to increased dynorphin release. Opioids also activate NMDA receptors, which in turn can cause an influx in calcium and potassium through activated channels leading to increased PKC. These mechanisms sensitize the postsynaptic neuron to pain (2) . Opioids induce the immune-system-related glial cells to release pro-inflammatory cytokines into dorsal horn of the spinal cord (3). DRG, dorsal root ganglion.
of mortality 106 . The protocol 105 also follows the wisdom for the use of off-label non-opioid pain medication substitutions such as tricyclic antidepressants (TCAs) or serotonin-noradrenaline reuptake inhibitors (SNRIs) to manage chronic abdominal pain 107, 108 . Gabapentin, a GABA analogue anticonvulsant, has shown promise in reducing opioid-induced hyperalgesia in patients with chronic pain by reducing central sensitization 109 . Preoperative gabapentin administration has been shown to significantly (P < 0.001) reduce postoperative opioid consumption in a meta-analysis of 1,793 patients who underwent abdominal, genitourinary, orthopaedic or thoracic surgery 110 . In a study of experimentally induced opioid withdrawal, co-administration of palonosetron (a 5-hydroxytryptamine receptor 3 (5-HT 3 ) antagonist) with hydroxyzine reduced the severity of withdrawal 111 . In addition, a Cochrane review published in 2017 identified buprenorphine as more effective than alternatives (for example, clonidine or lofexidine) in terms of severity of withdrawal, duration of treatment and likelihood of completing treatments 112 . Although developed for patients with NBS, this detoxification approach can be useful for moving from opioid to non-opioid pain management strategies for other patients with chronic abdominal pain, such as those with IBS, IBD or chronic pancreatitis. TCAs can improve the global symptoms of IBS 113 , and the noradrenergic modulatory action of TCAs might have anti-inflammatory effects 114 and might also inhibit TLR4 and TLR2 activation 94 . These TCA-linked pathways might also be beneficial for patients with IBD 115 . In a double-blind placebo-controlled trial of patients with IBD, the SNRI duloxetine was more efficacious than placebo in reducing depression, anxiety and the severity of gastrointestinal symptoms and chronic pain 116 . In addition, a study evaluating the effects of antidepressant therapies on global symptoms in patients with functional dyspepsia found that a TCA (amitriptyline) significantly reduced dyspepsia symptoms, whereas the selective serotonin reuptake inhibitor (SSRI) escitalopram did not 117 . Although SSRIs have not been shown to directly reduce abdominal pain, they can have an indirect effect by reducing associated anxiety and depression 118, 119 . Serotonergic psychoactive agents can affect other aspects of gastrointestinal functioning, such as accelerating small bowel transit, enhancing gastric accommodation, increasing colonic compliance and reducing sensations of distension 120 .
Alternative pharmacological treatments. Off-label medications such as mirtazapine, a tetracyclic anti depressant, can be prescribed as an alternative, or in addition, to TCAs or SNRIs, particularly if there is persistent sleep disturbance or nausea. Low-dose quetiapine, an antipsychotic, has also been recommended as an adjunct medication for pain in patients with refractory FGIDs but requires monitoring for possible adverse effects, such as metabolic syndrome, sedation and involuntary movements 121 . Anticonvulsant medications such as gabapentin and pregabalin have shown efficacy in reducing pain in patients with pancreatitis, IBS or IBD, mediated via effects in the brain [122] [123] [124] [125] [126] . Several review articles published elsewhere cover the risks and benefits of using other psychotropic agents for the management of abdominal pain 81, 87, 114, 127, 128 . 113, 116, [129] [130] [131] [132] [133] ; however, the findings of these meta-analyses should be interpreted in light of several general limitations, including overlap of included studies, small sample sizes, diversity of medications within each drug class, lack of uniformity of study endpoints and substantial heterogeneity among the studies analysed. In clinical studies, antispasmodics, peppermint oil, 5-HT 3 receptor antagonists and mixed opioid agents have also demonstrated efficacy for the treatment of pain and other symptoms in IBS 69, 134 . In terms of determining the best strategy for treating abdominal pain in each unique patient, previous exposure to psychotropic medications, drug allergies or sensitivities and the presence of comorbid medical and psychiatric conditions need to be considered. In addition, psychological drivers of pain (for example, the unconscious meaning of pain, secondary gain, poor cognitive flexibility, catastrophizing and fear-based attentional bias) can be important measurable confounders of other pain reduction strategies if not addressed as part of a comprehensive treatment plan (see BOX 2 for definitions of these psychological terms) 135, 136 . The management of OIC is also best achieved by stopping opioid use. Osmotic-type laxatives such as polyethylene glycol are most commonly used 79 . Alternatives to laxatives include more prolonged-release formulations that contain naloxone (an opioid antagonist), such as oxynal, which have also shown some benefit for improving bowel function 137 . Peripherally acting μ-opioid receptor antagonists (PAMORAs), including agents such as methylnaltrexone, alvimopan and naloxegol (NKTR-118), are efficacious for treating patients with more persistent OIC 138, 139 . These agents selectively bind
Box 1 | Risk mitigation when prescribing opioids
• Screen for opioid misuse by using available validated measures and avoid using opioids or taper the dose for patients with untreated substance abuse and/or dependence.
• Monitor appropriate use of opioids by using state or country prescription drug monitoring programmes and random toxicology screens.
• Form a treatment contract with patients that includes informed consent about risks versus benefits, such as the risk of overdose, addiction or serious adverse effects and increased risk of death.
• Discuss alternative treatment options with patients.
• Work within a multidisciplinary team (for example, physicians, nurses, mental health counsellors or addiction specialists and social workers) with resources for treating addiction and comorbid mental conditions. • Provide access to naloxone as a rescue medication.
• Provide the lowest possible dose of opioids, avoid 'as-needed' dosing and evaluate the risk-benefit ratio at least every 3 months. Doses >80 mg per day of morphine equivalent are best avoided owing to increased risks of adverse events.
• Taper long-acting opioids when risks are greater than benefits, and supplement the taper with non-opioid analgesics and behavioural interventions.
• Avoid concomitant use of benzodiazepines owing to increased risks of overdose and synergistic adverse effects.
• Provide careful documentation in the medical record.
to μ-opioid receptors in the gastrointestinal tract to block the peripheral effects of opioids while sparing the central opioid receptors that contribute to the analge sic effects 140 . Newer laxatives such as lubiprostone and prucalopride have shown efficacy in treating OIC. Lubiprostone activates chloride channel protein 2 in gastrointestinal epithelial cells, resulting in the secretion of chloride and ultimately softened stool consistency 141 . Prucalopride alters motility by activating selective 5-HT 4 receptors in the gut and has been shown to be effective in treating both chronic and opioid-induced constipation 142, 143 .
Other agents under development to treat OIC include the PAMORA naldemedine and the guanylate cyclase receptor agonist linaclotide 144 . Recommendations on • Symptom severity was significantly reduced in duloxetine group compared with placebo (P = 0.02) • Depression and anxiety were significantly reduced in duloxetine group compared with placebo (P = 0.041 and 0.049, respectively) • Physical, psychological and social dimensions of quality of life were significantly increased (P = 0.001, 0.038, and 0.015, respectively)
Kaplan et al.
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(Open-label pilot study) NA (13 patients with GAD and IBS) Duloxetine* 12 CGI, IBS symptoms, anxiety Significant improvements in symptom severity (P < 0.001), anxiety (P < 0.01), and CGI improvement (P < 0.001) and severity scales (P < 0.001) • Abdominal pain severity decreased by 56% (P < 0.0001) • Significant improvement in gastrointestinal symptoms (P < 0.001) and depression (P < 0.001) CGI, Clinical Global Impression scale; GAD, general anxiety disorder; MDD, major depressive disorder; NA, not applicable; RCT, randomized controlled trial; RR, relative risk; SNRI, serotonin-noradrenaline reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. *No comparison group.
initiating prescription therapies for OIC have previously been published and include the use of validated assessment tools to determine when treatments for OIC should be initiated 145 . Tools to assess for OIC, such as the Bowel Function Index 146 and the Patient Assessment of Constipation Symptoms 147 , include the evaluation of patient-reported bowel symptoms (for example, incomplete evacuation, straining, stool consistency and ease of defecation).
Nonpharmacological treatments for pain. In addition to non-opioid pharmacological management of pain, there is a growing body of literature supporting behavioural interventions as part of a comprehensive treatment plan for chronic abdominal pain, even when opioids are not involved 148 . In fact, there is a large body of literature supporting the use of various psycho social interventions, including cognitive behavioural therapy (CBT) or mindfulness training, for other types of chronic pain [149] [150] [151] . Several meta-analyses of randomized controlled trials targeting pain in IBS showed that antidepressants and behavioural interventions such as CBT outperformed placebo and standard medical treatments 129, [152] [153] [154] [155] . Cognitive behavioural interventions in addition to usual care also show promise in treating chronic pain in patients with IBD 156, 157 . However, pain in IBD studies is often measured as an item on another scale (for example, quality of life), and optimal efficacy of CBT has been hampered by study design issues and high attrition rates 158 . Other behavioural interventions, such as hypnosis and mindfulness meditation, have demonstrated efficacy in reducing psychiatric morbidity and chronic abdominal pain and improving quality of life across different gastrointestinal conditions (see TABLE 2 for a summary of meta-analyses evaluating the efficacy of behavioural interventions for chronic abdominal pain and associated symptoms) [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] . Behavioural interventions in patients with IBS appear to have their strongest effects on visceral pain via modulation of mood (anxiety, depression) 169 . Negative emotional states and stress have been shown to alter gut physiology, motility and sensitivity to nociceptive stimuli 170 . Neuroplastic changes in emotional and cognitive brain centres are known to amplify pain signals from the viscera 148, 171 . The fear-avoidance model of chronic pain has the most support in explaining how behavioural interventions can alter multiple aspects of central processing of pain, such as the sensory-discriminative and motivational-affective domains (discussed in detail elsewhere 148 ). These therapy-conditioned responses in the brain can influence the gastrointestinal tract by multiple pathways such as the autonomic nervous system, the hypothalamic-pituitary-adrenal stress axis, the immune system and the microbiome 172 .
Box 2 | Definitions of psychological confounders of opioid management
• Cognitive flexibility: The ability to adapt and apply a broad range of coping strategies to face new or unexpected challenges.
• Catastrophizing: A cognitive distortion or irrational thought that something is much worse than it actually is such that imagined worst-case scenarios are treated as inevitable.
• Fear-based attentional bias: The differential attention towards one stimulus class (for example, fear of pain) over another (neutral emotion) such that this selective processing of threatening information leads to hypervigilance and avoidance behaviour instead of adaptive coping or acceptance.
• Unconscious meaning of pain: A process by which an unbearable or unacceptable emotion (for example, rage) is converted to a more acceptable physical symptom; this process occurs outside of conscious awareness as a solution to avoid inner conflict.
• Secondary gain: The advantage that occurs in different domains (for example, increased attention from others, disability benefits, or being excused from responsibilities) owing to a real or stated illness. Many barriers to patients receiving nonpharmacological pain management therapies still exist, including geographical distance, shortage of behavioural intervention providers and long waiting lists 173 . The availability and demonstrated benefits of scripted hypnosis protocols can make this treatment feasible by trained medical staff 174 . The development of effective virtual behavioural therapy options (web-based approaches) to reduce pain has helped with the access problem, with patients now able to receive the adequate level of psychotherapy in the comfort of their homes, which is also associated with long-term efficacy [175] [176] [177] . A strong physician-patient relationship to facilitate management of pain and other medical conditions is critical, and this relationship should include good communication, empathic engagement and addressing problems and treatment as a dyadic team [178] [179] [180] [181] . This approach is particularly important as patients with pain often expect a quick fix without understanding the long-term consequences of opioid therapies 180, 182 . Working in a setting in which a broader team (nurses, social workers, behavioural specialists) is involved can help patients learn new coping strategies to reduce pain perception and help them understand the limitations associated with chronic opioid use. For managing people with gastrointestinal disorders, different models of integrated behavioural medical care and transdisciplinary treatment might be more effective than collaborative or integrated models, in which team members from different disciplines might be co-located but still practising in their particular niche 183 . Psychopathological considerations. Psychopathology, especially mood and anxiety disorders, is commonly associated with opioid use. In a study of 34,653 people, nonmedical opioid use was associated with mood disorders, major depressive disorder, bipolar disorder and anxiety disorders 184 . Psychiatric comorbidity is also associ ated with reduced opioid analgesia and increased opioid misuse 185 . Depressive symptoms have been reported to moderate the relationship between pain levels and opioid misuse 186 . Depression and anxiety were identified to mediate the relationship between catastrophizing and opioid misuse in another chronic pain population 187 .
There can be serious centrally mediated consequences of opioids 188 , as opioid receptors are also found in the brain. These receptors also bind endogenous opioids (endorphins) that are involved in pain perception and modulation of reward mechanisms and mood ( euphoria) 188 . These positive effects of opioids can be reinforcing, leading to repeated administration, which, in vulnerable individuals, becomes addiction. These risk factors for addiction include a biological predisposition for opioid-induced craving, loss of control or compulsive use 189 . It is important to distinguish between physical dependence (withdrawal syndrome following abrupt dose reduction or administration of an antagonist) and addiction (loss of control over use, continued use despite adverse consequences, preoccupation with obtaining and using the drug) 18 . An area that warrants attention is that relapse rates for patients with chronic pain who have been tapered from opioids are high and require long-term treatment algorithms to be developed 105 . One under-recognized cause of such relapse is opioid addiction. In a small study evaluating detoxification in NBS, the patients who had high relapse rates were those who had high opioid misuse scores, indicating that those addicted to opioids need greater intervention 105 . For patients who show signs of opioid addiction (problematic behaviours consistent with craving, loss of control or compulsive use), it is necessary to refer them to appropriate substance abuse clinics where they can have access to agonists (methadone or partial agonists such as buprenorphine) and appropriate counselling. In 2015, transdiagnostic and integrative therapies such as Acceptance and Commitment Therapy were found to be more efficacious than traditional CBT or 12-step programmes for patients with substance abuse disorders 190 . Opioid addiction can also lead to intravenous drug abuse 191 , increasing the risks of contracting HIV and hepatitis C 192, 193 . For treatment-refractory patients with chronic pain and addiction, several nonpharmacological biological interventions are in development. These options include peripheral nerve stimulation, as well as brain stimulation procedures such as transcranial magnetic stimulation, transcranial direct current stimulation, high-definition transcranial direct current stimulation and deep brain stimulation [194] [195] [196] [197] [198] . All of these approaches are thought to influence the modulation of pain in the peripheral or central nervous system by inhibiting the transmission of pain signals 194, 196 . For example, published case reports have indicated the subcutaneous placement of peripheral nerve stimulator electrodes in the location or dermatome associated with chronic abdominal pain improved pain severity and function and decreased the use of pain medications 194 . The risk-benefit ratio of these approaches for patients with abdominal pain has yet to be determined, and large controlled trials are needed 197, 198 . A small group of patients do benefit from chronic opioid use for pain management without developing tolerance, hyperalgesia or addiction 78 . For this group of patients, it is essential that prescribing physicians follow the legal recommendations in their state-run or national prescription drug monitoring programmes (PDMP), forming drug contracts with patients, including random toxicology screens, adhering to careful documentation in the electronic health records, using naloxone to treat opioid overdoses and continuing to explore non-opioid options with their patients. . In addition, Australia is seeking to establish a national PDMP 202 . PDMPs enable prescribers to assess aberrant behaviours (for example, 'doctor shopping') and have been associated with reductions in opioid prescribing 201 . The European Monitoring Centre for Drugs and Drug Addiction monitors trends in drug use for countries in the European Union and provides resources related to harm reduction interventions for drug use 203, 204 .
Conclusions
Opioid misuse is a global epidemic and has led to substantial increases in opioid-related abuse and mortality. Given the lack of evidence supporting the effectiveness of opioids for managing chronic pain, as well as the debilitating effects of those drugs on both the gastrointestinal and central nervous systems, alternative approaches to pain management in patients with gastrointestinal conditions must be employed. Alternatives to prescribing opioids in this population should include non-opioid pharmacological agents, behavioural interventions, strong physician-patient relationships and transdisciplin ary team approaches. This Review underscores the need for additional research (BOX 3) on non-opioid pharmacological and nonpharmacological interventions, as well as different formulations and/or delivery mechanisms of opioids for treating chronic abdominal pain in patients diagnosed with gastrointestinal disorders to reduce pain intensity, improve quality of life and avoid addiction.
